Antioxidant strategies in protection against neurodegenerative disorders

Bibliography

• GILBERT DL: Fifty years of radical ideas. Ann. NY Acad. Sci (2000) 899:1–14.
   PubMed Web of Science ®Google Scholar
• FANG YZ, YANG S, VVU G: Free radicals, antioxidants, and nutrition. Nutrition (2002) 18:872–879.
   PubMed Web of Science ®Google Scholar
• SYMONS MCR, GUTTERIDGE JMC: Free Radical and Iron. In: Chemistry Biology, and Medicine. Oxford Unversity Press, UK (1998):6–12.
   Google Scholar
• KANG D, NARABAYASHI H, SATA T, TAKESHIGE K: Kinetics of superoxide formation by respiratory chain NADH-dehydrogenase of bovine heart mitochondria. Biochem. (1983) 94:1301–1306.
   Google Scholar
• EVANS P, HALLIWELL B: Micronutrients: oxidant/antioxidant status. Br. J. Num (2001) 85\(Supp1.2):S67–S74.
   Google Scholar
• COYLE JT, PUTTFARCHEN P: Oxidative stress, glutamate and neurodegenerative disorders. Science (1993) 262:689–695.
   PubMed Web of Science ®Google Scholar
• MARLETTA MA: Nitric oxide synthase structure and mechanism. Biol. Chem. (1993) 268:12231–12234.
   Google Scholar
• HARE JM: Nitric oxide and excitation-contraction coupling. I MM. Cell. Cardiol. (2003) 35:719–29.
   PubMed Web of Science ®Google Scholar
• HALLIWELL B, GUTTERIDGE JMC: Oxygen toxicity, oxygen free radicals, transition metals and disease. Biochem. (1984) 219:1–4.
   Google Scholar
• LANDER HM: An essential role for free radicals and derived species in signal transduction. FASEB J. (1997) 11:118–124.
   PubMed Web of Science ®Google Scholar
• PRAST H, PHILIPPU A: Nitric oxide as modulator of neuronal function. Frog. Neurobiol (2001) 64:51–68.
   Google Scholar
• KELM M: The L-arginine-nitric oxide pathway in hypertension. Cum Hypertens Rep. (2003) 5:80–86.
   PubMedGoogle Scholar
• BOGDAN C: Nitric oxide and the immune response. Nat. Immunol (2001) 2:907–916.
   PubMed Web of Science ®Google Scholar
• KELM M: Fundamental aspects of reactive oxygen species, or what's the matter with oxygen? Ann. NY Acad. Sci (1999) 893:13–18.
   PubMedGoogle Scholar
• AMES BN: Endogenous DNA damage as related to cancer and aging. Mutat. Res. (1989) 214:41–46.
   PubMedGoogle Scholar
• STADTMAN ER: Protein oxidation in aging and age-related diseases. Ann. NY Acad. Sci (2001) 928:22–38.
   PubMed Web of Science ®Google Scholar
• KHAN FH, SAHA M, CHAKRABARTI S: Dopamine-induced protein damage in mitochondrial-synaptosomal fraction of rat brain. Brain. Res. (2001) 895:245–249.
   PubMed Web of Science ®Google Scholar
• GUTTERIDGE JM, HALLIWELL B: Reoxygenation injury and antioxidant protection: a tale of two paradoxes. Arch. Biochem. Biophys. (1990) 283:223–226.
   PubMed Web of Science ®Google Scholar
• ESTERBAUER H, ECKL P, ORTNER A: Possible mutagens derived from lipids and lipid precursors. Mutat. Res. (1990) 238:223–233.
   PubMed Web of Science ®Google Scholar
• BRIVIBA K, SIES H: Non-enzymatic antioiddative defense systems. In: Natural Antioxidants in Human Health and Disease. Frei B (Ed.) Academic Press, San Diego, USA (1994):107–128.
   Google Scholar
• AHMAD S: Antioxidant mechanisms of enzymes and proteins. In Oxidative Stress and Antioxidative Defenses in Biology Ahmad S (Ed.) Chapman and Hall. New York, USA (1995):238–272.
   Google Scholar
• MAISTER A: On the antioxidant effect of ascorbic acid and glutathione. Biochem. Pharmacol (1992) 44:1905–1915.
   PubMedGoogle Scholar
• MOOSMANN B, BEHL C: Antioxidants as treatment for neurodegenerative disorders, Expert Opin. Investing. Drugs (2002) 11:1407–1435.
   PubMed Web of Science ®Google Scholar
• ••An extensive review on antioxidants andneurodegenerative disorders.
   Google Scholar
• LIU B, GAO HM, WANG JY, JEOHN GH, COOPER CL, HONG JS: Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. NY Acad. Sci. (2002) 962:318–331.
   PubMed Web of Science ®Google Scholar
• CALINGASAN NY, GIBSON GE: Vascular endothelium is a site of free radical production and inflammation in areas of neuronal loss in thiamine-deficient brain. Ann. NY Acad. Sci (2000) 903:353–356.
   PubMedGoogle Scholar
• MCGEER EG, MCGEER PL: Inflammatory processes in Alzheimer's disease. Frog. Neuropsychopharmacol. Biol. Psychiatry (2003) 27:741–749.
   PubMed Web of Science ®Google Scholar
• BEAL MF: Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. NY Acad. Sci (2003) 991:120–131.
   PubMedGoogle Scholar
• BAZAN NG, COLANGELO V, LUKIW WJ: Prostaglandins and other lipid mediators in Alzheimer's disease. Prostaglandins Other Lipid Mediat (2002) 68:197–210.
   PubMedGoogle Scholar
• VAN DER VEEN RC, HENTONDR, INCARDONNA F, HOFMAN FM: Extensive peroxynitrite activity during progressive stages of central nervous system inflammation. J. Neuroimmund (1997) 77:1–7.
   PubMedGoogle Scholar
• LIU Y, ZHU B, WANG X et al.: Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis.' Neuroimmunol (2003) 139:27–35.
   PubMed Web of Science ®Google Scholar
• MOHAMED A, SHOKER A, BENDJELLOUL F et at Improvement of experimental allergic encephalomyelitis (EAE) by thymoquirione; an oxidative stress inhibitor. Biomed. Sci. Instrum (2003) 39:440–445.
   PubMedGoogle Scholar
• MARTINEY JA, RAJAN AJ, CHARLES PC et al.: Prevention and treatment of experimental autoimmune encephalomyelitis by CNI-1493, a macrophage-deactivating agent.' Immunol (1998) 160:5588–5595.
   Google Scholar
• ROBBERECHT W, SAPP P, VIAENE MU et al.: Cu/Zn superoxide dismutase activity in familial and soporadic amytrophic lateral scelerosis." Neurochem. (1994) 62:1384–1387.
   Google Scholar
• LUETJENS CM, BUI NT, SENGPIEL B et al.: Delayed mitochondrial dysfunction in excitotoxic neuron death: cytochrome c release and a secondary increase in superoxide production. Neurosci. (2000) 20:5715–5723.
   Google Scholar
• CALINGASAN NY, CHUN WJ, PARK LC, UCHIDA K, GIBSON GE: Oxidative stress is associated with region-specific neuronal death during thiamine deficiency. I Neuropathol Exp. Neurol. (1999) 58:946–958.
   PubMed Web of Science ®Google Scholar
• EVANS PH, YANO E, KLINOWSKI J, PETERHANS E: Oxidative damage in Alzheimer's dementia, and the potential etiopathogenic role of aluminosilicates, microglia and micronutrient interactions. EXS(1992) 62:178–189.
   PubMedGoogle Scholar
• HALLIWELL B, CLEMENT MV, LONG LH: Hydrogen peroxide in the human body. FEBS Lett. (2000) 486:10–13.
   PubMed Web of Science ®Google Scholar
• NUNOMURA A, PERRY G, ALIEV G et al.: Oxidative damage is the earliest event in Alzheimer's disease. " Neuropathol Exp. Neural. (2001) 60:759–767.
   Google Scholar
• SWERDLOW RH, PARKS JK, PATTEE G, PARKER WD Jr: Role of mitochondria in amyotrophic lateral sclerosis. Neuron Disord (2000) 1:185–190.
   Google Scholar
• DIKRANIAN K, ISHIMARU MJ, TENKOVA T et al.: Apoptosis in the in vivo mammalian forebrain. Neurobiol Dis. (2001) 8:359–379.
   PubMed Web of Science ®Google Scholar
• EBADI M, SRINIVASAN SK, BAXI MD: Oxidative stress and antioxidant therapy in Parkinson's disease. Frog. Neurobiol. (1996) 48:1–19.
   Google Scholar
• PITCHUMONI SS, DORAISWAMY PM: Current status of antioxidant therapy for Alzheimer's disease. Am. Geriatr (1998) 46:1566–1572.
   PubMed Web of Science ®Google Scholar
• OKEN BS, STORZBACH DM, KAYE JA:The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease. Arch. Neural. (1998) 55:1409–1415.
   PubMed Web of Science ®Google Scholar
• BARNEOUD P, CURET O: Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin, on moter performance in a transgenic model of amyotrophic lateral sclerosis. Exp. Neurol (1999) 155:234–251.
   Google Scholar
• GREENWOOD J: The blood-retinal barrier in experimental autoimmune uveoretinitis (EAU): a review. Carr. Eye Res. (1992) 11 (Suppl.):25–32.
   Google Scholar
• GILGUN-SHERKI Y, MELAMED E, OFFEN D: Oxidative stress-induced neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology (2001) 40:959–975.
   PubMed Web of Science ®Google Scholar
• •This paper deals with the relationship between drugs and the BBB.
   Google Scholar
• WEISER H, VECCHI M: Stereoisomers of a-tocopheryl acetate. II. Biopotencies of all eight stereoisomers, individually or in mixtures, as determined by the rat resorption/gestation test. Int. Vitam. Nutr. Res. (1982) 52:351–370.
   Google Scholar
• MARTIN A, CHERUBINI A, ANDRES-LACUEVA C, PANIAGUA M, JOSEPH J: Effects of fruits and vegetables on levels of vitamins E and C in the brain and their association with cognitive performance. Nutr. Health Aging. (2002) 6:392–404.
   PubMedGoogle Scholar
• BLATT DH, LEONARD SW, TRABER MG: Vitamin E kinetics and the function of tocopherol regulatory proteins. Nutrition (2001) 17:799–805.
   PubMed Web of Science ®Google Scholar
• GOTI D, HAMMER A, GALLA HJ, MALLE E, SATTLER W: Uptake of lipoprotein-associated a-tocopherol by primary porcine brain capillary endothelial cells. J. Neurochem. (2000) 74:1374–1383.
   PubMed Web of Science ®Google Scholar
• WALLSTROM P, WIRFALT E, LAHMANN PH, GULLBERG B, JANZON L, BERGLUND G: Serum concentrations of I3-carotene and a-tocopherol are associated with diet, smoking, and general and central adiposity. Am. .1. Clin. Nutr (2001) 73:777–785.
   PubMed Web of Science ®Google Scholar
• VATASSERY GT, FAHN S, KUSKOWSKI MA: a-Tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. Parkinson Study Group. Neurology (1998) 50:1900–1902.
   PubMed Web of Science ®Google Scholar
• LEONARD SW, TERASAWA Y, FARESE RV jR, TRABER MG: Incorporation of deuterated RRR- or all-rac-a-tocopherol in plasma and tissues of a-tocopherol transfer protein-null mice. Am.Clin. Nutr (2002) 75:555–560.
   PubMed Web of Science ®Google Scholar
• COPP RP, WISNIEWSKI T, HENTATI F, LARNAOUT A, BEN HAMIDA M, KAYDEN HJ: Localization of a-tocopherol transfer protein in the brains of patients with ataxia with vitamin E deficiency and other oxidative stress-related neurodegenerative disorders. Brain Res. (1999) 822:80–87.
   PubMed Web of Science ®Google Scholar
• KOLL M, BEESO JA, KELLY FJ et al.: Chronic a-tocopherol supplementation in rats does not ameliorate either chronic or acute alcohol-induced changes in muscle protein metabolism. Clin. Sci (2003) 104:287–294.
   Google Scholar
• SACHECK JM, MILBURY PE, CANNON JG, ROUBENOFF R, BLUMBERG JB: Effect of vitamin E and eccentric exercise on selected biomarkers of oxidative stress in young and elderly men. Free Radic. Biol. Med. (2003) 34:1575–1588.
   PubMed Web of Science ®Google Scholar
• BARCLAY LR, ARTZ JD, MOWAT JJ: Partitioning and antioxidant action of the water-soluble antioxidant, Trolox, between the aqueous and lipid phases of phosphatidylcholine membranes: MC tracer and product studies. Biochim. Biophys. Acta. (1995) 1237:77–85.
   PubMed Web of Science ®Google Scholar
• GUO Q, PACKER L: Ascorbate-dependent recycling of the vitamin E homologue Trolox by dihydrolipoate and glutathione in murine skin homogenates. Free Radic. Biol. Med. (2000) 29:368–374.
   PubMed Web of Science ®Google Scholar
• MULLER DPR: Vitamin E and neurological function: lessons from patients with abetalipoproteinaemia. Redox Rep. (1995) 1:239–245.
   PubMedGoogle Scholar
• DE KUMAR A, RUKMINI D: Physiological antioxidants and antioxidant enzymes in vitamin E-deficient rats. Toxicol Lett. (1988) 44:47–54.
   PubMedGoogle Scholar
• CRANDON JH, LUND CC, DILL DB: Experimental human scurvy. N Engl. Med. (1940) 223:353–369.
   Google Scholar
• ENGLARD S, SEIFTER S: The biochemical functions of ascorbic acid. Ann. Rev Num (1986) 6:365–406.
   PubMed Web of Science ®Google Scholar
• CHANVITAYAPONGS S, DRACZYNSKA-LUSIAK B, SUN AY: Amelioration of oxidative stress by antioxidants and resveratrol in PC12 cells. Neuroreport (1997) 8:1499–1502.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN K, BALAKUMAR BS, PANNEERSELVAM C: Effects of ascorbic acid and a-tocopherol on arsenic-induced oxidative stress. Hum. Exp. ToxicoL (2002) 21:675–680.
   PubMed Web of Science ®Google Scholar
• DE MARTINIS BS, BIANCHI MD: Effect of vitamin C supplementation against cisplatin-induced toxicity and oxidative DNA damage in rats. Pharmacol Res. (2001) 44:317–320.
   PubMed Web of Science ®Google Scholar
• CHAN AC: Partners in defense. Vitamin E and vitamin C. Can. I Physic] Pharmacol (1993) 7:725–731.
   Google Scholar
• HORNIG D: Distribution of ascorbic acid, metabolites and analogues in man and animals. Ann. NY Acad. Sci. (1975) 258:103–118.
   PubMed Web of Science ®Google Scholar
• ARGUS DB, GAMBHIR SS, PARDRIDGE WM et al: Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J. Clin. Invest. (1997) 100:2842–2848.
   PubMedGoogle Scholar
• ••An important paper dealing with the BBBtransport mechanism of vitamin C.
   Google Scholar
• DENEKE SM: Thiol-based antioxidants. Carr. Top. Cell. Regal (2000) 36:151–180.
   PubMedGoogle Scholar
• PEARCE RK, OWEN A, DANIEL S, JENNER P, MARSDEN CD: Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural. Transm. (1997) 104:661–677.
   PubMed Web of Science ®Google Scholar
• SCHULZ JB, LINDENAU J, SEYFRIED J, DICHGANS J: Glutathione, oxidative stress and neurodegeneration. Eur. Biochein (2000) 267:4904–4911.
   PubMedGoogle Scholar
• YAMAMOTO M, SAKAMOTO N, IWAI A et al.: Protective actions of YM-737, a new glutathione analog, against cerebral ischemia in rats. Res. Commun. Chem. Pathol Pharmacol (1993) 81:221–232.
   PubMedGoogle Scholar
• GIESS R, HOLTMANN B, BRAGA M et al.: Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am. J. Hum. Genet (2002) 70:1277–1286.
   PubMed Web of Science ®Google Scholar
• KISH SJ, MORITO C, HORNYKIEWICZ O: Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. (1985) 58:343–346.
   PubMed Web of Science ®Google Scholar
• SAGARA Y, DARGUSCH R, KLIER FG: Increased antioxidant enzyme activity in amyloid 3 protein-resistant cells." Neurosci (1996) 16:497–505.
   PubMed Web of Science ®Google Scholar
• NAKAO N, FRODL EM, WIDNER H et al.: Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nat. Med. (1995) 1:226–231.
   PubMed Web of Science ®Google Scholar
• MUGESH G, DU MONT WW: Structure-activity correlation between natural glutathione peroxidase (GPx) and mimics: a biomimetic concept for the design and synthesis of more efficient GPx mimics. Chemistry(2001) 7:1365–1370.
   PubMed Web of Science ®Google Scholar
• •An interesting paper dealing with the mechanism of GPx mimetics.
   Google Scholar
• IMAI H, GRAHAM DI, MASAYASU H, MACRAE IM: Antioxidant ebselen reduces oxidative damage in focal cerebral ischemia. Free Radic. Biol. Med (2003) 34:56–63.
   PubMed Web of Science ®Google Scholar
• BURGER ME, ALVES A, CALLEGARI L et al.: Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Frog. Neuropsychopharmacol Biol. Psychiatry (2003) 27:135–140.
   PubMed Web of Science ®Google Scholar
• CASTAGNE V, CLARKE PG: Neuroprotective effects of a new glutathione peroxidase mimetic on neurons of the chick embryo's retina. J. Neurosci. Res. (2000) 59:497–503.
   PubMedGoogle Scholar
• PONG K: Oxidative stress in neurodegenerative disease: therapeutic implications for superoxide dismutase mimetics. Expert. Opin. BiolTher. (2003) 3:127–139.
   PubMed Web of Science ®Google Scholar
• MOLLACE V, IANNONE M, MUSCOLI C et al: The protective effect of M-40401, a superoxide dismutase mimetic, on post-ischemic brain damage in Mongolian gerbils. BMC Pharmacol (2003) Jun 16 [Electronically published ahead of print].
   Google Scholar
• WU DC, JACKSON-LEWIS V, VILA M et al.: Blockade of microglial activation is neuroprotective in the 1-methy1-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. " Neurosci. (2002) 22:1763–1771.
   Google Scholar
• DOCTROW SR, HUFFMAN K, MARCUS CB et al.: Salen-manganese complexes: combined superoxide dismutase/catalase mimics with broad pharmacological efficacy. Adv. Pharmacol. (1997) 38:247–269.
   PubMedGoogle Scholar
• JUNG C, RONG Y, DOCTROW S, BAUDRY M, MALFROY B, XU Z: Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci. Lett. (2001) 304:157–160.
   PubMed Web of Science ®Google Scholar
• HARDELAND R, BALZER I, POEGGELER B et al.: On the primary functions of melatonin in evolution: mediation of photoperiodic signals in a unicell, photooxidation, and scavenging of free radicals.j. Pineal Res. (1995) 18:104–111.
   PubMed Web of Science ®Google Scholar
• REITER RJ: Pineal melatonin: cell biologyof its synthesis and of its physiological interactions. Endocrine Rev (1991) 12:151–180.
   PubMed Web of Science ®Google Scholar
• MANCHESTER LC, TAN DX, REITER RJ, PARK W, MONIS K, QI W: High levels of melatonin in the seeds of edible plants: possible function in germ tissue protection. Life Sci (2000) 67:3023–3029.
   PubMed Web of Science ®Google Scholar
• TAN DX, MANCHESTER LC, HARDELAND R: Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. Pineal. Res. (2003) 34:75–78.
   PubMed Web of Science ®Google Scholar
• CHEN G, HUO Y, TAN DX, LIANG Z, ZHANG W, ZHANG Y: Melatonin in Chinese medicinal herbs. Life Sci. (2003) 73:19–26.
   PubMed Web of Science ®Google Scholar
• TRICOIRE H, LOCATELLI A, CHEMINEAU P, MALPAUX B: Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology (2002) 143:84–90.
   PubMed Web of Science ®Google Scholar
• TAN DX, CHEN LD, POEGGELER B, MANCHESTER LC, REITER RJ: Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocrine (1993) 1:57–60.
   Google Scholar
• REITER RJ: Oxidative damage in the central nervous system: protection by melatonin. Frog. Neurobiol. (1998) 56:359–384.
   Google Scholar
• •Discusses the relationship of melatonin with several neurodegenerative conditions.
   Google Scholar
• REITER RJ, GUERRERO JM, GARCIA JJ, ACUNA-CASTROVIEJO D: Reactive oxygen intermediates, molecular damage and aging: relation to melatonin. Ann. NY Acad. Sci (1998) 854:410–454.
   PubMed Web of Science ®Google Scholar
• BARLOW-WALDEN L, REITER RJ, ABE M et al.: Melatonin stimulates brain glutathione peroxidase activity. Neurochem. Int (1995) 26:947–502.
   Google Scholar
• URATA Y, HONMA S, GOTO S et al.: Melatonin induces y-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radic. Biol. Med (1999) 27:838–847.
   PubMed Web of Science ®Google Scholar
• TAN DX, REITER RJ, MANCHESTER LC et al.: Chemical and physical properties and potential mechanisms: melatonin as a broad spectrum antioxidant and free radical scavenger. Curc Top. Med. Chem. (2002) 2:181–197.
   PubMedGoogle Scholar
• •Discusses in detail the mechanism of melatonin as an antioxidant.
   Google Scholar
• HUSSON I, MESPLES B, BAC P, VAMECQ J, EVRARD P, GRESSENS P: Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann. Neurol (2002) 51:82–92.
   PubMed Web of Science ®Google Scholar
• SHIDA CS, CASTRUCCI AML, LAMY-FREUND MT: High melatonin solubility in aqueous medium. J. Pineal Res. (1994) 16:198–201.
   PubMed Web of Science ®Google Scholar
• COSTA EJX, SHIDA CS, BIAGGI MH, ITO AS, LAMY-FREUND MT: How melatonin interacts with lipid bilayes: a study by fluorescence and ESR spectroscopies. FEBS Lett (1997) 416:103–106.
   PubMedGoogle Scholar
• CERAULO L, FERRUGIA M, TESORIERE L, SEGRETO S, LIVREA MA, LIVERT VT: Interactions of melatonin with membrane models: portioning of melatonin in AOT and lecithin reversed micelles. J. Pineal Res. (1999) 26:108–112.
   PubMed Web of Science ®Google Scholar
• MARTIN M, MACIAS M, ESCAMES G, LEON J, ACUNA-CASTROVIEJO D: Melatonin but not vitamins C and E maintains glutathione homeostasis in t-butyl hydroperwdde-induced mitochondrial oxidative stress. FASEB. I (2000) 14:2128–2130.
   PubMedGoogle Scholar
• MENENDEZ-PELAEZ A, POEGGELER B, REITER RJ, BARLOW-WALDEN L, PABLOS MI, TAN DX: Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence." Cell. Biochem. (1993) 53:373–382.
   PubMed Web of Science ®Google Scholar
• CHYAN YJ, POEGGELER B, OMAR RA et al.: Potent neuroprotective properties against the Alzheimer I3-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. Biol. Chem. (1999) 274:21973–21942.
   Google Scholar
• CHAN TY, TANG PL: Characterization of antioxidant effects of melatonin and related indoleamines M vitro. J. Pineal Res. (1996) 20:187–191.
   PubMed Web of Science ®Google Scholar
• NAPPI AJ, VASS E: Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid, and selected catechols. Biochem. Biophys. Acta (1997) 1336:295–302.
   PubMed Web of Science ®Google Scholar
• FEIGIN VL, LAWES CM, BENNETT DA, ANDERSON CS: Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. (2003) 2:43-53. Ha BERGEN DC, SILBERBERG D: Nervous system disorders: a global epidemic. Arch. Neurol. (2002) 59:1194–1196.
   Google Scholar
• WHO: The World Health Report 2000, Geneva: WHO (2000).
   Google Scholar
• WHITE BC, SULLIVAN JM, DEGRACIA DJ et al.: Brain ischemia and reperfusion: molecular mechanisms of neuronal injury. Neurol. Sci. (2000) 179(S1-2):1–33.
   Web of Science ®Google Scholar
• HUANG Z, HUANG PL, PANAHIAN N, DALKARA T, FISHMAN MC, MOSKOWITZ MA. Effects of cerebral ischemia in mice deficient in neuronal nitric oxide synthase. Science. (1994) 265:1883–1885.
   PubMed Web of Science ®Google Scholar
• KINOUCHI H, EPSTEIN CJ, MIZUE T, CARLSON E, CHEN SF, CHAN PH: Attenuation of focal cerebral ischemic injury in transgenic mice overexpressing CuZn superoxide dismutase. Proc. Nati Acad. Sci. USA (1991) 88:11158–11162.
   PubMed Web of Science ®Google Scholar
• TAGAMI M, IKEDA K, YAMAGATA K et al.: Vitamin E prevents apoptosis in hippocampal neurons caused by cerebral ischemia and reperfusion in stroke-prone spontaneously hypertensive rats. Lab. Invest. (1999) 79:609–615.
   PubMed Web of Science ®Google Scholar
• VAN DER WORP HB, THOMAS CE, KAPPELLE LJ, HOFFMAN WP, DE WILDT DJ, BAR PR Inhibition of iron-dependent and ischemia-induced brain damage by the a-tocopherol analogue MDL-74,722. Exp. Neurni (1999) 155:103–108.
   PubMedGoogle Scholar
• DAGA MK, MADHUCHHANDA, MISHRA TK, MOHAN A: Lipid peroxide, I3-carotene and a-tocopherol in ischaemic stroke and effect of exogenous vitamin E supplementation on outcome. J. Assoc. Physicians India. (1997) 45:843–846.
   PubMedGoogle Scholar
• YOCHUM LA, FOLSOM AR, KUSHI LH: Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. Am. J. Clin. Num. (2000) 72:476–483.
   PubMed Web of Science ®Google Scholar
• SCIAMANNA MA, LEE CP: Ischemia/ reperfusion-induced injury of forebrain mitochondria and protection by ascorbate. Arch. Biochem. Biophys. (1993) 305:215–24.
   PubMed Web of Science ®Google Scholar
• RANJAN A, THEODORE D, HARAN RP, CHANDY MJ: Ascorbic acid and focal cerebral ischaemia in a primate model. Acta Neuman,: (1993) 123:87–91.
   Google Scholar
• HENRY PT, CHANDY MJ: Effect of ascorbic acid on infarct size in experimental focal cerebral ischaemia and reperfusion in a primate model. Acta Neuman]: (1998) 140:977–980.
   PubMed Web of Science ®Google Scholar
• CHERUBINI A, POLIDORI MC, BREGNOCCHI M et al: Antioxidant profile and early outcome in stroke patients. Stroke (2000) 31:2295–2300.
   PubMed Web of Science ®Google Scholar
• POLIDORI MC, FRET B, CHERUBINI A etal.: Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radic Biol. Med (1998) 25:561–567.
   Google Scholar
• POLIDORI MC, MECOCCI P, FRET B: Plasma vitamin C levels are decreased and correlated grain damage in patients with intracranial hemorrhage head trauma. Stroke (2001) 32:898–902.
   PubMed Web of Science ®Google Scholar
• WOLF PA: Epidemiology and risk factor management. In: Printer on Cerebrovascular Disease (Welch KMA, Caplan LR, Reis DJ, Siesjo BK, Weir B (Eds) Academic Press, San Diego, USA (1997):751–757.
   Google Scholar
• PARK EM, CHOI JH, PARK JS, HAN MY, PARK YM: Measurement of glutathione oxidation and 8-hydroxy-2'-deoxyguanosine accumulation in the gerbil hippocampus following global ischemia. Brain. Res. Protoc. (2000) 6:25–32.
   PubMedGoogle Scholar
• MARTINEZ G, CARNAZZA ML, CAMPISI A et al: Effects of glutathione depletors on post-ischemic reperfusion in rat brain. Neurochern. Res. (1998) 23:961–968.
   PubMedGoogle Scholar
• SEKHON B, SEKHON C, KHAN M, PATEL SJ, SINGH I, SINGH AK N-acetyl cysteine protects against injury in a rat model of focal cerebral ischemia. Brain Res. (2003) 971:1–8.
   PubMed Web of Science ®Google Scholar
• JOHSHITA H, SASAKI T, MATSUI T et al: Effects of ebselen (PZ51) on ischaemic brain oedema after focal ischaemia in cats. Acta. Neurochic Sapp]. (1990) 51:239–241.
   PubMedGoogle Scholar
• DAWSON DA, MASAYASU H, GRAHAM DI, MACRAE IM: The neuroprotective efficacy of ebselen (a glutathione peroxidase mimic) on brain damage induced by transient focal cerebral ischaemia in the rat. Neurosci. Lett. (1995) 185:65–69.
   PubMed Web of Science ®Google Scholar
• TAKASAGO T, PETERS EE, GRAHAM DI, MASAYASU H, MACRAE IM: Neuroprotective efficacy of ebselen, an anti-oxidant with anti-inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion. Br. PhannacoL (1997) 122:1251–1256.
   Google Scholar
• NAMURA S, NAGATA I, TAKAMI S, MASAYASU H, KIKUCHI H: Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice. Stroke (2001) 32:1906–1911.
   PubMed Web of Science ®Google Scholar
• YAMAGUCHI T, SANO K, TAKAKURA K et al.: Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group. Stroke (1998) 29:12–17.
   PubMed Web of Science ®Google Scholar
• BAKER K, MARCUS CB, HUFFMAN K, KRUK H, MALFROY B, DOCTROW SR: Synthetic combined superoxide dismutase/ catalase mimetics are protective as a delayed treatment in a rat stroke model: a key role for reactive oxygen species in ischemic brain injury. I Pharmacol. Exp. The]: (1998) 284:215–221.
   PubMed Web of Science ®Google Scholar
• SHIMIZU K, RAJAPAKSE N, HORIGUCHI T, PAYNE RM, BUSIJA DW: Protective effect of a new non-peptidyl mimetic of SOD, M40401, against focal cerebral ischemia in the rat. Brain Res (2003) 963:8–14.
   PubMedGoogle Scholar
• MANEV H, UZ T, KHARLAMOV A, J00 JY: Increased brain damage after stroke or excitotoxic seizures in melatonin-deficient rats. FASEB J. (1996) 10:1546–1551.
   PubMed Web of Science ®Google Scholar
• KILIC E, OZDEMIR YG, BOLAY H, KELESTIMUR H, DALKARA T: Pinealectomy aggravates and melatonin administration attenuates brain damage in focal ischemia. Cereb. Blood Flow Metab. (1999) 19:511–516.
   PubMed Web of Science ®Google Scholar
• WAKATSUKI A, OKATANI Y, IZUMIYA C, IKENOUE N: Melatonin protects against ischemia and reperfusion-induced oxidative lipid and DNA damage in fetal rat brain.' Pineal Ret (1999) 26:147–152.
   PubMed Web of Science ®Google Scholar
• GUERRERO JM, REITER RJ, ORTIZ GG, PABLOS MI, SEWERYNEK E, CHUANG Melatonin prevents increases in neural nitric oxide and cyclic GMP production after transient brain ischemia and reperfusion in the Mongolian gerbil (Meriones unguiculatus)..f. Pineal Res. (1997) 23:24–31.
   PubMed Web of Science ®Google Scholar
• CHO S, JOH TH, BAIK HH, DIBINIS C, VOLPE BT: Melatonin administration protects CA1 hippocampal neurons after transient forebrain ischemia in rats. Brain Res (1997) 755:335–338.
   PubMedGoogle Scholar
• LI XJ, ZHANG LM, GU J, ZHANG AZ, SUN FY: [Melatonin decreases production of hydroxyl radical during cerebral ischemia-reperfusion.] Zhongguo Yao Li Xue Bao (1997) 18:394-396. Chinese.
   Google Scholar
• LETECHIPIA-VALLEJO G, GONZALEZ-BURGOS I, CERVANTES M: Neuroprotective effect of melatonin on brain damage induced by acute global cerebral ischemia in cats. Arch. Med. Res. (2001) 32:186–192.
   PubMedGoogle Scholar
• CUZZOCREA S, COSTANTINO G, GITTO E et al.: Protective effects of melatonin in ischemic brain injury../. Pineal Res. (2000) 29:217–227.
   PubMed Web of Science ®Google Scholar
• BORLONGAN CV, YAMAMOTO M, TAKEI N et al.: Glial cell survival is enhanced during melatonin-induced neuroprotection against cerebral ischemia. FASEB J. (2000) 14:1307–1317.
   PubMed Web of Science ®Google Scholar
• LING X, ZHANG LM, LU SD, LI XJ, SUN FY: [Protective effect of melatonin on injuried cerebral neurons is associated with bc1-2 protein over-expression]. Zhongguo Yao Li Xue Bao (1999) 20:409-414. Chinese.
   Google Scholar
• KONDOH T, UNEYAMA H, NISHINO H, TORII K: Melatonin reduces cerebral edema formation caused by transient forebrain ischemia in rats. Life Sci (2002) 72:583–590.
   PubMed Web of Science ®Google Scholar
• EL-ABHAR HS, SHAALAN M, BARAKAT M, EL-DENSHARY ES: Effect of melatonin and nifedipine on some antioxidant enzymes and different energy fuels in the blood and brain of global ischemic rats. Pineal Res. (2002) 33:87–94.
   PubMed Web of Science ®Google Scholar
• SUN FY, LIN X, MAO LZ et al: Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. Pineal Res. (2002) 33:48–56.
   PubMed Web of Science ®Google Scholar
• PEI Z, PANG SF, CHEUNG RT: Pretreatment with melatonin reduces volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Pineal Res. (2002) 32:168–172.
   PubMed Web of Science ®Google Scholar
• PEI Z, HO HE CHEUNG RT: Pre-treatment with melatonin reduces volume of cerebral infarction in a permanent middle cerebral artery occlusion stroke model in the rat. Neurosci. Lett. (2002) 18:141–144.
   Google Scholar
• PEI Z, PANG SF, CHEUNG RT: Administration of melatonin after onset of ischemia reduces the volume of cerebral infarction in a rat middle cerebral artery occlusion stroke model. Stroke (2003) 34:770–775.
   PubMed Web of Science ®Google Scholar
• FIORINA P, LATTUADA G, PONARI O, SILVESTRINI C, DALLAGLIO P: Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients. Lancet (1996) 347:692–693.
   PubMedGoogle Scholar
• PANG SF, LI Y, JIANG DH, CHANG B, XIE BL: Acute cerebral hemorrhage changes the nocturnal surge of plasma melatonin in humans. Pineal Res. (1990) 9:193–208.
   PubMedGoogle Scholar
• FIORINA P, LATTUADA G, SILVESTRINI C, PONARI O, DALL'AGLIO P: Disruption of nocturnal melatonin rhythm and immunological involvement in ischaemic stroke patients. Scand. Immunol (1999) 50:228–231.
   PubMed Web of Science ®Google Scholar
• BELOOSESKYY, GRINBLAT J, LAUD ON M, GROSMAN B, STREIFLERJY, ZISAPEL N: Melatonin rhythms in stroke patients. Neurosci. Lett. (2002) 319:103–106.
   PubMedGoogle Scholar
• EBLY EM, PARHAD IM, HOGAN DB, FUNG TS: Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology (1994) 44:1593–1600.
   PubMed Web of Science ®Google Scholar
• SYKES CM, MARKS DF, MCKINLEY JM: Alzheimer's disease and associated disorders: project funding opportunities within the European community. Alzheimer Dis. Assoc. Disord. (2001) 15:102–105.
   PubMedGoogle Scholar
• BROOKMEYER R, GRAYS, KAWAS C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Jim. .1 Public Health. (1998) 88:1337–1342.
   Google Scholar
• NUSSBAUM RL, ELLIS CE: Alzheimer's disease and Parkinson's disease. N Engl.' Merl (2003) 348:1356–1364.
   PubMed Web of Science ®Google Scholar
• ••A review representing the currentunderstanding of AD and PD.
   Google Scholar
• BORCHELT DR, THINAKARAN G, ECKMAN CB et at Familial Alzheimer's disease-linked presenilin 1 variants elevate A31-42/1-40 ratio M vitro and in vivo. Neuron (1996) 17:1005–1013.
   PubMed Web of Science ®Google Scholar
• STRITTMATTER WJ, ROSES AD. Apolipoprotein E and Alzheimer's disease. Ann. Rev Neurosci. (1996) 19:53–77.
   PubMed Web of Science ®Google Scholar
• NUNOMURA A, PERRY G, ALIEV G: et al.: Oxidative damage is the earliest event in Alzheimer's disease.' Neuropathol Exp. Neural. (2001) 60:759–767.
   PubMed Web of Science ®Google Scholar
• GIBSON GE, HUANG HM: Oxidative processes in the brain and non-neuronal tissues as biomarkers of Alzheimer's disease. Front Biosci (2002) 7:1007–1015.
   PubMed Web of Science ®Google Scholar
• TUPPO EE, FORMAN LJ: Free radical oxidative damage and Alzheimer's disease. J. Am. Osteopath. Assoc (2001) 101 (12Suppl.Pt1):S11–15.
   Google Scholar
• MARIDONNEAU-PARINI I, TRINGALE SM, TAUBER Al: Identification of distinct activation pathways of the human neutrophil NADPH-oxidase. I Immunol (1986) 137:2925–2929.
   PubMed Web of Science ®Google Scholar
• BUTTERFIELD DA: Amyloid13-peptide (1–42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radii: Res (2002) 36:1307–1313.
   Google Scholar
• MCLELLAN ME, KAJDASZ ST, HYMAN BT, BACSKAI BJ: h7 vivoimaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. Neurosci (2003) 23:2212–2217.
   Google Scholar
• RUTTEN BP, STEINBUSCH HW, KORR H, SCHMITZ C: Antioxidants and Alzheimer's disease: from bench to bedside (and back again). Carr. Opin. Clin. Num. Metab. Care (2002) 5:645–651.
   PubMed Web of Science ®Google Scholar
• BUTTERFIELD DA, KOPPALT, SUBRAMANIAM R, YATIN S: Vitamin E as an antioxidant/free radical scavenger against amyloid 13-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: insights into Alzheimer's disease. Rev Neurosci (1999) 10:141–149.
   PubMed Web of Science ®Google Scholar
• YATIN SM, VARADARAJAN S, BUTTERFIELD DA: Vitamin E prevents Alzheimer's amyloid 3-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. Alzheimers Dis. (2000) 2:123–131.
   PubMedGoogle Scholar
• MUNOZ FJ, OPAZO C, GIL-GOMEZ G et al.: Vitamin E but not 1713-estradiol protects against vascular toxicity induced by 3-amyloid wild type and the Dutch amyloid variant. Neurosci (2002) 22:3081–3089.
   Google Scholar
• PRATICO D, URYU K, SUNG S, TANG S, TROJANOWSKI JQ, LEE VM: Aluminum modulates brain amyloidosis through oxidative stress in APP transgenic mice. FASEB (2002) 16:1138–1140.
   PubMed Web of Science ®Google Scholar
• SANO M, ERNESTO C, THOMAS RG et al.: A controlled trial of selegiline, a-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's disease Cooperative Study. N Engl. I Med. (1997) 336:1216–1222.
   Google Scholar
• THOMAS A, IACONO D, BONANNI L, D'ANDREAMATTE0 G, ONOFRJ M: Donepea rivastigmine, and vitamin E in Alzheimer's disease: a combined P300 event-related potentials/neuropsychologic evaluation over 6 months. Clin. Neuropharmacol (2001) 24:31–42.
   PubMed Web of Science ®Google Scholar
• MORRIS MC, EVANS DA, BIENIAS JL et al.: Dietary intake of antioxidant nutrients and the risk of incident Alzheimer's disease in a biracial community study. JAMA. (2002) 287:3230–3237.
   PubMed Web of Science ®Google Scholar
• ENGELHART MJ, GEERLINGS MI, RUITENBERG et al.: Dietary intake of antioxidants and risk of Alzheimer's disease. JAMA. (2002) 287:3223–3229.
   PubMed Web of Science ®Google Scholar
• VARNER AE: Antioxidants and risk of Alzheimer's disease. JAMA. (2002) 288:2265–2266.
   PubMedGoogle Scholar
• LUCHSINGER JA, TANG MX, SHEA S, MAYEUX R: Antioxidant vitamin intake and risk of Alzheimer's disease. Arch. Neurol (2003) 60:203–208.
   PubMed Web of Science ®Google Scholar
• PARASKEVAS GP, KAPAKI E, LIBITAKI G, ZOURNAS C, SEGDITSA I, PAPAGEORGIOU C: Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer's disease. Acta Neurol Scand. (1997) 96:88–90.
   PubMedGoogle Scholar
• RIVIERE S, BIRLOUEZ-ARAGON I, NOURHASHEMI F, VELLAS B: Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int. j Ceriatr. Psychiatry (1998) 13:749–754.
   PubMed Web of Science ®Google Scholar
• PREHN JH, BINDOKAS VP, JORDAN J et al.: Protective effect of transforming growth factor-I3 1 on 3-amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol (1996) 49:319–328.
   PubMed Web of Science ®Google Scholar
• MEDINA S, MARTINEZ M, HERNANZ A: Antioxidants inhibit the human cortical neuron apoptosis induced by hydrogen peroxide, tumor necrosis factor a, dopamine and 3-amyloid peptide 1-42. Free Radic. Res. (2002) 36:1179–1184.
   PubMed Web of Science ®Google Scholar
• PERRY TL, YONG VW, BERGERON C, HANSEN S, JONES K: Amino acids, glutathione, and glutathione transferase activity in the brains of patients with Alzheimer's disease. Ann. Neurol (1987) 21:331–336.
   PubMed Web of Science ®Google Scholar
• KONINGS CH, KUIPER MA, TEERLINK T, MULDER C, SCHELTENS P, WOLTERS EC: Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. I Nemo]. Sci. (1999) 168:112–115.
   Google Scholar
• GUM, OWEN AD, TOFFA SE et at.: Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. Neurol Sci (1998) 158:24–29.
   Google Scholar
• CECCHI C, LATORRACA S, SORBI S, IANTOMASI T, FAVILLI F, VINCENZINI MT et at anhatione level is altered in lymphoblasts from patients with familial Alzheimer's disease. Neurosci. Lett. (1999) 275:152–154.
   PubMed Web of Science ®Google Scholar
• LOVELL MA, EHMANN WD, BUTLER SM, MARKESBERY WR: Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology (1995) 45:1594–1601.
   PubMed Web of Science ®Google Scholar
• MARCUS DL, THOMAS C, RODRIGUEZ C et al.: Increased perwddation and reduced antioxidant enzyme activity in Alzheimer's disease. Exp. Neurol (1998) 150:40–44.
   PubMed Web of Science ®Google Scholar
• PEREIRA C, SANTOS MS, OLIVEIRA C.: Involvement of oxidative stress on the impairment of energy metabolism induced by Al3 peptides on PC12 cells: protection by antioxidants. Neurobiol D AK (1999) 6:209–219.
   Google Scholar
• OLIVIERI G, BAYSANG G, MEIER F et al.: N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on I3-amyloid secretion and tau phosphorylation. Neurochem. (2001) 76:224–233.
   PubMed Web of Science ®Google Scholar
• TOHGI H, ABET, TAKAHASHI S, KIMURA M, TAKAHASHI J, KIKUCHI T: Concentrations of serotonin and its related substances in the cerebrospinal fluid in patients with Alzheimer type dementia. Neurosci. Lett. (1992) 141:9–12.
   PubMedGoogle Scholar
• LIU RY, ZHOU JN, VAN HEERIKHUIZE J, HOFMAN MA, SWAAB DF: Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer's disease, and apolipoprotein E-epsilon4/4 genotype. Clin. EndocrinoL Metab. (1999) 84:323–327.
   Google Scholar
• REBECK GW, REITER JS, STRICKLAND DK, HYMAN BT: Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron (1993) 11:575-580. Hz. MISHIMA K, TOZAWA T, SATOH K, MATSUMOTO Y, HISHIKAWA Y, OKAWA M: Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol. Psychiatry (1999) 45:417–421.
   Google Scholar
• SAVASKAN E, OLIVIERI G, MEIER F et al.: Increased melatonin la-receptor immunoreactivity in the hippocampus of Alzheimer's disease patients. Pinea/Res. (2002) 32:59–62.
   Google Scholar
• PAPPOLLA MA, SOS M, OMAR RA et al.: Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J. Neurosci (1997) 17:1683–1690.
   PubMed Web of Science ®Google Scholar
• PAPPOLLA MA, CHYAN YJ, BOZNER P et al.: Dual anti-amyloiddogenic and antioxidant properties of melatonin. A new therapy for Alzheimer's disease. In: Research Advance in Alzheimer's disease Iqbal K, Mortimer J, Winblad B, Wisniewski HM (Eds) Wiley and Sons, New York, USA (1999):661–669.
   Google Scholar
• PAPPOLLA M, BOZNER P, SOTO C et al.: Inhibition of Alzheimer I3-fibrillogenesis by melatonin. Biol. Chem. (1998) 273:7185–7188.
   Google Scholar
• SHEN YX, XU SY, VVEI W, WANG XL, WANG H, SUN X: Melatonin blocks rat hippocampal neuronal apoptosis induced by amyloid I3-peptide 25-35.1 Pineal Res. (2002) 32:163–167.
   PubMedGoogle Scholar
• SHEN YX, VVEI W, XU SY: Protective effects of melatonin on cortico-hippocampal neurotoxicity induced by amyloid I3-peptide 25-35. Acta Pharmacol Sin. (2002) 23:71–76.
   PubMedGoogle Scholar
• POEGGELER B, MIRAVALLE L, ZAGORSKI MG et al.: Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Al3 peptide. Biochemistry (2001) 40:14995–15001.
   PubMed Web of Science ®Google Scholar
• OLIVIERI G, HESS C, SAVASKAN E et al.: Melatonin protects SHSY5Y neuroblastoma cells from cobalt-induced oxidative stress, neurotoxicity and increased I3-amyloid secretion. J. Pineal Res. (2001) 31:320–325.
   PubMed Web of Science ®Google Scholar
• BOZNER P, GRISHKO V, LED OUX SP, WILSON GL, CHYAN YC, PAPPOLLA MA: The amyloid 13 protein induces oxidative damage of mitochondrial DNA. I Neuropathol Exp. NeuroL (1997) 56:1356-1362. zoz. SHEN YX, XU SY, VVEI W et al.: The protective effects of melatonin from oxidative damage induced by amyloid I3-peptide 25–35 in middle-aged rats. J. Pineal Res. (2002) 32:85–89.
   Google Scholar
• MATSUBARA E, BRYANT-THOMAS T, PACHECO QUINTO J et al: Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. Neurochem. (2003) 85:1101–1108.
   PubMed Web of Science ®Google Scholar
• BRUSCO LI, MARQUES M, CARDINALI DP: Monozygotic twins with Alzheimer's disease treated with melatonin: case report. I Pineal Res. (1998) 25:260–263.
   PubMed Web of Science ®Google Scholar
• MAURIZI CP. Alzheimer's disease: role for mitochondrial damage, the hydroxyl radical, and cerebrospinal fluid deficiency of melatonin. Med. Hypotheses(2001) 57:156–160.
   Google Scholar
• BRUSCO LI, MARQUES M, CARDINALI DP: Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. NeuroendocrionoL Lett. (1998) 19:111–115.
   Google Scholar
• COHEN-MANSFIELD J, GARFINKEL D, LIPSON S: Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study. Arch. Cerontr. Ceriatr. (2000) 31:65–76.
   Google Scholar
• ASAYAMA K, YAMADERA H, ITO T, SUZUKI H, KUDO Y, ENDO S: Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in alzheimer type dementia. Nippon Med. Sch. (2003) 70:334–341.
   PubMedGoogle Scholar
• BRUCE AJ, MALFROY B, BAUDRY M: I3-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger. Proc. Natl. Acad. Sci. USA (1996) 93:2312–2316.
   PubMed Web of Science ®Google Scholar
• TANNER CM, GOLDMAN SM: Epidemiology of Parkinson's disease. Neurol Gin. (1996) 14:317–335.
   Google Scholar
• LYRAS L, PERRY RH, PERRY EK et al.: Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies. Neurochem. (1998) 71:302–312.
   PubMed Web of Science ®Google Scholar
• JENNER P: Oxidative stress in Parkinson's disease. Ann. Neurol (2003) 53\(Supp1.3):S26–36.
   Google Scholar
• GRAHAM DG: Oxidative pathways for catecholamines in genesis of neuromelanin and cytotoxic quinones. MoL Pharmacol (1978) 14:633–643.
   PubMed Web of Science ®Google Scholar
• OLANOW CW: Oxidation reactions in Parkinson's disease. Neurology (1990) 40\(Supp1.3):32–37.
   Google Scholar
• PEDROSA R, SOARES-DA-SILVA P: Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine(L-DOPA) and dopamine. Br. I Pharmacol (2002) 137:1305–1313.
   PubMed Web of Science ®Google Scholar
• ADAMS JD Jr, CHANG ML, KLAIDMAN L, ADAMS JD jR, CHANG ML, KLAIDMAN L: Parkinson's disease-redox mechanisms. Curr. Med. Chem. (2001) 8:809–814.
   PubMedGoogle Scholar
• CUTILLAS B, AMBROSIO S, UNZETA M: Neuroprotective effect of the monoamine oxidase inhibitor PF-9601N [N-(2-propyny1)-2-(5-benzyloxy-indoly1) methylamine] on rat nigral neurons after 6-hydroxydopamine-striatal lesion. Neurosci. Lett. (2002) 329:165–168.
   PubMedGoogle Scholar
• GOOD PF, OLANOW CW, PERL DP: Neuromelanin-contng neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brant Res (1992) 593:343–346.
   PubMed Web of Science ®Google Scholar
• BLUM D, TORCH S, LAMBENG N et al.: Molecular pathways involved in the neurotoxicity of 6-0HDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Frog. Neurobiol (2001) 65:135–172.
   Google Scholar
• MARSDEN CD, JENNER PG: The significance of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine. Ciba Found Symp. (1987) 126:239–256.
   PubMedGoogle Scholar
• GERLACH M, RIEDERER P: Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.' Neural. Transm. (1996) 103:987–1041.
   PubMed Web of Science ®Google Scholar
• GERLACH M, RIEDERER P, PRZUNTEK H, YOUDIM MB: MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. Pharmacol (1991) 208:273–286.
   PubMed Web of Science ®Google Scholar
• CASSARINO DS, PARKS JK, PARKER WD Jr, BENNETT JP Jr: The parkinsonian neurotwdn MPP± opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim. Biophys. Acta (1999) 1453:49–62.
   PubMed Web of Science ®Google Scholar
• GOMEZ C, REIRIZ J, PIQUE M, GIL J, FERRER I, AMBROSIO S: Low concentrations of 1-methy1-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells.' Neurosci Res. (2001) 63:421–428.
   Google Scholar
• STEPHANS SE, MILLER GW, LEVEY AI, GREENAMYRE JT: Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. Neurotoxicology (2002) 23:569–580.
   PubMedGoogle Scholar
• TORNERO D, CENA V, GONZALEZ-GARCIA C, JORDAN J: The role of the mitochondrial permeability transition pore in neurodegenerative processes. Rev. Neurol (2002) 35:354–61.
   PubMedGoogle Scholar
• EBADI M, GOVITRAPONG P, SHARMA S et al.: Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of Parkinson's disease. Biol. Signals Recept (2001) 10:224–253.
   Google Scholar
• TOHGI H, ABE T, SAHEKI M, HAMATO F, SASAKI K, TAKAHASHI S: Reduced and oxidized forms of glutathione and a-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment. Neurosci Lett. (1995) 184:21–24.
   PubMed Web of Science ®Google Scholar
• MOLINA JA, DE BUSTOS F, JIMENEZ-JIMENEZ FJ et al.: Cerebrospinal fluid levels of a-tocopherol (vitamin E) in Parkinson's disease. Neural. Transm. (1997) 104:1287–1293.
   PubMed Web of Science ®Google Scholar
• STORCH A, KAFTAN A, BURKHARDT K, SCHWARZ J: 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism. Neural. Transm. (2000) 107:281–293.
   PubMed Web of Science ®Google Scholar
• AKANEYA Y, TAKAHASHI M, HATANAKA H: Involvement of free radicals in MPP± neurotoxicity against rat dopaminergic neurons in culture. Neurosci. Lett. (1995) 193:53–56.
   PubMed Web of Science ®Google Scholar
• SANCHEZ-RAMOS JR, MICHEL P, WEINER WJ, HEFTI F: Selective destruction of cultured dopaminergic neurons from fetal rat mesencephalon by 1-methy1-4-phenylpyridinium: cytochemical and morphological evidence. J Neurochem. (1988) 50:1934–1944.
   PubMedGoogle Scholar
• GONZALEZ-POLO RA, SOLER G, ALVAREZ A, FABREGAT I, FUENTES JM: Vitamin E blocks early events induced by 1-methy1-4-phenylpyridinium (MPP±) in cerebellar granule cells. Neurochem. (2003) 84:305–315.
   PubMed Web of Science ®Google Scholar
• CADET JL, KATZ M, JACKSON-LEWIS V, FAHN S: Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-0HDA) in rats: behavioral and biochemical evidence. Brain Res. (1989) 476:10–15.
   PubMed Web of Science ®Google Scholar
• HEIM C, KOLASIEWICZ W, KURZ T, SONTAG KH: Behavioral alterations after unilateral 6-hydroxydopamine lesions of the striatum. Effect of a-tocopherol. Pol. Pharmacol. (2001) 53:435–448.
   PubMedGoogle Scholar
• ROGHANI M, BEHZADI G: Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res. (2001) 892:211–217.
   PubMed Web of Science ®Google Scholar
• PERRY TL, YONG VW, CLAVIER RM et al.: Partial protection from the dopaminergic neurotwdn N-methy1-4-pheny1-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. (1985) 60:109–114.
   PubMedGoogle Scholar
• PERRY TL, YONG VW, HANSEN S et al.: a-tocopherol and 13-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methy1-4-phenyl-1,2,3,6-tetrahydropyridine. Neural. Sci (1987) 81:321–331.
   PubMedGoogle Scholar
• SELLEY ML: (E)-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. (1998) 2:169–174.
   Google Scholar
• BARC S, PAGE G, BARRIER L, HUGUET F, FAUCONNEAU B: Progressive alteration of neuronal dopamine transporter activity in a rat injured by an intranigral injection of MPP*. Brain Res. (2002) 941:72–81.
   PubMedGoogle Scholar
• GONG L, DAIGNEAULT EA, ACUFF RV, KOSTRZEWA Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. Neuroreport (1991) 2:544–546.
   PubMedGoogle Scholar
• MIHATSCH W, RUSS H, GERLACH M, RIEDERER P, PRZUNTEK H: Treatment with antioxidants does not prevent loss of dopamine in the striatum of MPTP-treated common marmosets: preliminary observations. Neural Transm. Park. Dis. Dement. Sect. (1991) 3:73–78.
   PubMedGoogle Scholar
• PARKINSON STUDY GROUP: Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl. I Med. (1993) 328: 176–183.
   PubMed Web of Science ®Google Scholar
• FAHN S: A pilot trial of high-dose a-tocopherol and ascorbate in early Parkinson's disease. Ann. Neural. (1992) 32(Suppl.):S128–132.
   Google Scholar
• FARISS MW, ZHANG JG: Vitamin E therapy in Parkinson's disease. Toxicology (2003) 189:129–146.
   PubMed Web of Science ®Google Scholar
• •An interesting paper related to vitamin E and PD.
   Google Scholar
• GOLBE LI, FARRELL TM, DAVIS PH: Case-control study of early life dietary factors in Parkinson's disease. Arch. Neurol (1988) 45:1350–1353.
   PubMedGoogle Scholar
• DE RIJK MC, BRETELER MM, DEN BREEIJEN JH et al.: Dietary antioxidants and Parkinson's disease. The Rotterdam Study. Arch. Neurol (1997) 54:762–765.
   PubMed Web of Science ®Google Scholar
• ZHANG SM, HERNAN MA, CHEN H, SPIEGELMAN D, WILLETT WC, ASCHERIO A: Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology (2002) 59:1161–1169.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-CALLE P, JIMENEZ-JIMENEZ FJ, MOLINA JA et al.: Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease. Neurol Sci. (1993) 118:25–28.
   Google Scholar
• YAPA SC: Detection of subclinical ascorbate deficiency in early Parkinson's disease. Detection of subclinical ascorbate deficiency in early Parkinson's disease. Public Health. (1992) 106:393–395.
   Google Scholar
• KING D, PLAYFER JR, ROBERTS NB: Concentrations of vitamins A, C and E in elderly patients with Parkinson's disease. Postgrad Med. J. (1992) 68:634–637.
   PubMedGoogle Scholar
• SOTO-OTERO R, MENDEZ- ALVAREZ E, HERMIDA-AMEIJEIRAS A, MUNOZ-PATINO AM, LABANDEIRA-GARCIA JL: Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. Neurochem. (2000) 74:1605–1612.
   PubMed Web of Science ®Google Scholar
• CHOI HY, SONG JH, PARK DK, ROSS GM: The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics. NeuroscL Lett. (2000) 296:81–84.
   PubMedGoogle Scholar
• SAWADA H, SHIMOHAMA S, KAWAMURA T et al.: Mechanism of resistance to NO-induced neurotoxicity in cultured rat dopaminergic neurons. Neurosci. Res. (1996) 46:509–518.
   Google Scholar
• SCHEIDER WL, HERSHEY LA, VENA JE, HOLMLUND T, MARSHALL JR, FREUDENHEIM: Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mo v. Disord. (1997) 12:190–196.
   PubMed Web of Science ®Google Scholar
• KONINGS CH, KUIPER MA, TEERLINK T, MULDER C, SCHELTENS P, WOLTERS EC: Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J. Neurol Sci. (1999) 168:112–115.
   PubMedGoogle Scholar
• SIAN J, DEXTER DT, LEES AJ, DANIELS, AGID Y, JAVOY-AGID et al.: Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann. Neurol (1994) 36:333–334.
   Google Scholar
• OWEN AD, SCHAPIRA AH, JENNER P, MARSDEN CD: Oxidative stress and Parkinson's disease. Ann. NY Acad. ScL (1996) 786:217–223.
   PubMed Web of Science ®Google Scholar
• SIAN J, DEXTER DT, LEES AJ, DANIEL S, JENNER P, MARSDEN CD: Glutathione-related enzymes in brain in Parkinson's disease. Ann. Neurnl (1994) 36:356–361.
   PubMed Web of Science ®Google Scholar
• JENNER P: Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. (1998) 13 (Supp1.1):24–34.
   Google Scholar
• TARIQ M, KHAN HA, AL MOUTAERY K, AL DEEB S: Protective effect of quinacrine on striatal dopamine levels in 6-0HDA and MPTP models of Parkinsonism in rodents. Brain Res. Bull (2001) 54:77–82.
   PubMedGoogle Scholar
• DESOLE MS, ESPOSITO G, FRESU L et al.: Correlation between 1-methy1-4-phenylpyridinium ion (MPP±) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine (MPTP)-treated rat. Neurosci. Lett. (1993) 161:121–123.
   PubMedGoogle Scholar
• MCNAUGHT KS, JENNER P: Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methy1-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures. Neurochem. (1999) 73:2469–2476.
   PubMed Web of Science ®Google Scholar
• OFFEN D, ZIV I, STERNIN H, MELAMED E, HOCHMAN A: Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp. Neurol (1996) 141:32–39.
   PubMed Web of Science ®Google Scholar
• WULLNER U, LOSCHMANN PA, SCHULZ JB et al.: Glutathione depletion potentiates MPTP and MPP± toxicity in nigral dopaminergic neurones. Neuroreport (1996) 7:921–923.
   PubMed Web of Science ®Google Scholar
• GARCIA JC, REMIRES D, LEIVA A, GONZALEZ R: Depletion of brain glutathione potentiates the effect of 6-hydroxydopamine in a rat model of Parkinson's disease. Mol Neurosci (2000) 14:147–153.
   PubMed Web of Science ®Google Scholar
• PILEBLAD E, MAGNUSSON T, FORNSTEDT B: Reduction of brain glutathione by L-buthionine sulfoximine potentiates the dopamine-depleting action of 6-hydroxydopamine in rat striatum. Neurochem. (1989) 52:978–980.
   PubMedGoogle Scholar
• DESOLE MS, ESPOSITO G, ENRICO P et al.: Effects of ageing on 1-methy1-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxic effects on striatum and brainstem in the rat. Neurosci. Lett. (1993) 159:143–146.
   PubMedGoogle Scholar
• PERRY TL, YONG VW, CLAVIER RM et al.: Partial protection from the dopaminergic neurotoxin N-methy1-4-phenyl-1,2,3, 6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci Lett. (1985) 60:109–114.
   PubMedGoogle Scholar
• MOUSSAOUI S, OBINU MC, DANIEL N, REIBAUD M, BLANCHARD V, IMPERATO A. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurnl (2000) 166:235–245.
   PubMed Web of Science ®Google Scholar
• FERTL E, AUFF E, DOPPELBAUER A, WALDHAUSER F: Circadian secretion pattern of melatonin in Parkinson's disease. Neural. Transm. Park. Dis. Dement. Sect. (1991) 3:41–47.
   PubMedGoogle Scholar
• FERTL E, AUFF E, DOPPELBAUER A, WALDHAUSER F: Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of 1-dopa. I Neural. Transm. Park. Dis. Dement. Sect. (1993) 5:227–234.
   PubMedGoogle Scholar
• CATALA MD, CANETE-NICOLAS C, IRADI A, TARAZONA PJ, TORMOS JM, PASCUAL-LEONE A: Melatonin levels in Parkinson's disease: drug therapy versus electrical stimulation of the internal globus pallidus. Exp. Gerontol (1997) 32:553–558.
   PubMed Web of Science ®Google Scholar
• GHAEMI M, RUDOLF J, HILKER R, HERHOLZ K, HEISS W-D: Increased pineal F-dopa uptake is related to severity of Parkinson's disease - A PET study. I Pineal Res. (2001) 30:213–219.
   PubMedGoogle Scholar
• MAYO JC, SAINZ RM, URIA H, ANTOLIN I, ESTEBAN MM, RODRIGUEZ C: Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. Pineal Res. (1998) 24:179–192.
   PubMed Web of Science ®Google Scholar
• MAYO JC, SAINZ RM, URIA H, ANTOLIN I, ESTEBAN MM, RODRIGUEZ: Inhibition of cell proliferation: a mechanism likely to mediate the prevention of neuronal cell death by melatonin. Pineal Res. (1998) 25:12–18.
   PubMed Web of Science ®Google Scholar
• MAYO JC, SAINZ RM, ANTOLIN I, RODRIGUEZ C: Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage. Brain Res. (1999) 818:221–227.
   PubMed Web of Science ®Google Scholar
• PARK JW, YOUN YC, KWON OS, JANG YY, HAN ES, LEE CS: Protective effect of serotonin on 6-hydroxydopamine-and dopamine-induced oxidative damage of brain mitochondria and synaptosomes and PC12 cells. Neurochem. Int. (2002) 40:223–233.
   PubMedGoogle Scholar
• IACOVITTI L, STULL ND, JOHNSTON K: Melatonin rescues dopamine neurons from cell death in tissue culture models of oxidative stress. Brain Res. (1997) 768:317–326.
   PubMed Web of Science ®Google Scholar
• STULL ND, POLAN DP, IACOVITTI L: Antioxidant compounds protect dopamine neurons from death due to oxidative stress in vitro. Brain Res. (2002) 931:181–185.
   PubMedGoogle Scholar
• TENN CC, NILES LP: Central-type benzodiazepine receptors mediate the antidopaminergic effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: involvement of a GABAergic mechanism.' Pharmacol Exp. The]: (1995) 274:84–89.
   Google Scholar
• KIM YS, J00 WS, JIN BK, CHO YH, BAIK HH, PARK CW: Melatonin protects 6-0HDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport (1998) 9:2387–2390.
   PubMed Web of Science ®Google Scholar
• J00 WS, JIN BK, PARK CW, MAENG SH, KIM YS: Melatonin increases striatal dopaminergic function in 6-0HDA-lesioned rats. Neuroreport (1998) 9:4123–4126.
   PubMedGoogle Scholar
• DABBENI-SALA F, DI SANTO S, FRANCESCHINI D, SKAPER SD, GIUSTI P: Melatonin protects against 6-0HDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB (2001) 15:164–170.
   PubMed Web of Science ®Google Scholar
• AGUIAR LM, VASCONCELOS SM, SOUSA FC, VIANA GS: Melatonin reverses neurochemical alterations induced by 6-0HDA in rat striatum. Life Sci (2002) 70:1041–1051.
   PubMed Web of Science ®Google Scholar
• ACUNA-CASTROVIEJO D, COTO-MONTES A, GAIA MONTI M, ORTIZ GG, REITER RJ: Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Se/. (1997) 60:PL23–29.
   PubMed Web of Science ®Google Scholar
• TANG YP, MA YL, CHAO CC, CHEN KY, LEE EH: Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments. Neurosci. Res (1998) 53:593–604.
   Google Scholar
• ORTIZ GG, CRESPO-LOPEZ ME, MORAN-MOGUEL C, GARCIA JJ, REITER RJ, ACUNA-CASTROVIEJO D: Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuroendocrinol Lett. (2001) 22:101–108.
   PubMed Web of Science ®Google Scholar
• LI XJ, GU J, LU SD, SUN FY: Melatonin attenuates MPTP-induced dopaminergic neuronal injury associated with scavenging hydroxyl radical. Pinea/Res. (2002) 32:47–52.
   Google Scholar
• ANTOLIN I, MAYO JC, SAINZ P.M et al.: Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res (2002) 943:163–173.
   Google Scholar
• KHALDY H, ESCAMES G, LEON J, BIKJDAOUENE L, ACUNA-CASTROVIEJO D: Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol Aging (2003) 24:491–500.
   PubMed Web of Science ®Google Scholar
• ITZHAK Y, MARTIN JL, BLACK MD, ALI SF: Effect of melatonin on methamphetamine- and 1-methy1-4-pheny1-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity and methamphetamine-induced behavioral sensitization. Neurophannacology (1998) 37:781–791.
   PubMedGoogle Scholar
• VAN DER SCHYF CJ, CASTAGNOLI K, PALMER S, HAZELWOOD L, CASTAGNOLI N JR: Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum. Neurotox. Res. (2000) 1:261–269.
   PubMedGoogle Scholar
• MORGAN WW, NELSON JF: Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway. Brain Res. (2001) 921:115–121.
   PubMed Web of Science ®Google Scholar
• YAN MT. Melatonin has antioxidant effects in the brain. J. Pineal Res. (2002) 33:125–126.
   PubMedGoogle Scholar
• VATASSERY GT, NELSON MJ, MALETTA GJ, KUSKOWSKI MA: Vitamin E (tocopherols) in human cerebrospinal fluid. Am. I Clin. Num (1991) 53:95–99.
   PubMedGoogle Scholar
• VATASSERY GT, ANGERHOFER CK, PETERSON FJ: Vitamin E concentrations in the brains and some selected peripheral tissues of selenium-deficient and vitamin E-deficient mice. 1 Neurochem. (1984) 42:554–558.
   PubMed Web of Science ®Google Scholar
• MARTIN A, PRIOR R, SHUKITT-HALE B, CAO G, JOSEPH JA: Effect of fruits, vegetables, or vitamin E-rich diet on vitamins E and C distribution in peripheral and brain tissues: implications for brain function. J. GerontoL A Biol. ScL Med. Sci. (2000) 55:B144–B151
   Google Scholar
• ACUNA-CASTROVIEJO D, ESCAMES G, CARAZO A, LEON J, KHALDY H, REITER RJ: Melatonin, mitochondrial homeostasis and mitochondrial-related diseases. Curr: Top. Med. Chem. (2002) 2:133–151.
   PubMedGoogle Scholar
• MAHAL HS, SHARMA HS, MUKHERJEE T: Antioxidant properties of melatonin: a pulse radiolysis study. Free Radic. Biol. Med. (1999) 26:557–565
   PubMed Web of Science ®Google Scholar
• GITTO E, TAN DX, REITER RJ et al: Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. " Pharm. Pharmacol (2001) 53:1393–1401.
   PubMed Web of Science ®Google Scholar
• TAN DX, HARDELAND R, MANCHESTER LC et al.: Mechanistic and comparative studies of melatonin and classic antioxidants in terms of their interactions with the ABTS cation radical. J. Pineal Res. (2003) 34:249–259.
   PubMed Web of Science ®Google Scholar
• KONTUSH A, MANN U, ARLT S et aL: Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease. Free Radic. Biol. Med. (2001) 31:345–354.
   PubMed Web of Science ®Google Scholar
• CUZZOCREA S, REITER RJ: Pharmacological actions of melatonin in acute and chronic inflammation. Curr. Top. Med. Chem. (2002) 2:153–165.
   PubMedGoogle Scholar
• OLANOW CW: Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. J. Neural. Transm. Sapp] (1996) 48:75–84.
   PubMedGoogle Scholar
• MALLY J, KOVACS AB, STONE TW: Delayed development of symptomatic improvement by (-)-deprenyl in Parkinson's disease. " Nemo]. Sci. (1995) 134:143–145.
   Google Scholar